Related Experiment Videos
Escalating interferon-alpha-2b dose for patients with chronic hepatitis C
E De La Riva1, R J Garcia-Carrasquillo, M D Puppo
1Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Hepato-Gastroenterology
|February 10, 1999
Summary
Escalating interferon-alpha-2b doses for chronic hepatitis C non-responders is ineffective. Increased doses led to significant toxicity and intolerance, with no observed treatment benefits for patients with hepatitis C.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C remains a significant global health concern.
- Interferon-alpha-2b is a standard treatment for hepatitis C.
- Identifying optimal treatment strategies for non-responders is crucial.
Purpose of the Study:
- To evaluate the efficacy of escalating interferon-alpha-2b dosage in chronic hepatitis C patients.
- To assess the safety and tolerability of higher interferon-alpha-2b doses in non-responders.
Main Methods:
- Patients with chronic hepatitis C received initial treatment with 3,000,000 units of interferon-alpha-2b thrice weekly.
- Non-responders at 12 weeks had their dose escalated to 3,000,000 units daily.
- Further non-responders had their dose escalated to 5,000,000 units daily.
Main Results:
- Only 1 of 29 patients (3%) responded to the 3,000,000 units daily dose, with 41% discontinuing due to adverse events.
- None of the 14 patients escalated to 5,000,000 units daily responded, and 43% discontinued treatment.
- Escalated doses showed no significant virologic response and high rates of intolerance.
Conclusions:
- Increasing interferon-alpha-2b dosage beyond initial treatment is not effective for chronic hepatitis C non-responders.
- Higher doses are associated with increased toxicity and poor patient tolerance.
- Alternative treatment strategies should be considered for patients refractory to standard interferon therapy.